ABBV
Another door opens for Skyrizi
AbbVie says the European Commission approved Skyrizi (risankizumab) for pediatric patients aged 6 and up with moderate to severe plaque psoriasis who are candidates for systemic therapy. Translation: the drug’s label just got bigger, which is exactly what pharma companies love to see when they’re trying to keep a franchise from aging like milk.
Why this matters
This approval was based on the Phase 3 OptIMMize-1 and OptIMMize-2 trials, and AbbVie also highlighted a new 55 mg pre-filled syringe for kids under 40 kg. That’s not just a packaging tweak — it’s the kind of practical detail that can make a therapy actually usable in the real world, which tends to be important when you’re treating smaller patients.
The business angle
For investors, label expansions are the pharma version of finding extra pockets in a jacket you already bought. You’re not launching a brand-new drug, but you are extending the life and reach of an existing one. And since Skyrizi has already become one of AbbVie’s key growth pillars, every new indication helps reinforce the company’s post-Humira story.
Big picture
AbbVie doesn’t need every approval to be a moonshot. Sometimes it just needs a steady drip of new uses to keep the revenue machine humming — and this one gives Skyrizi another lane to run in.